Oncogene-induced senescence in pituitary adenomas and carcinomas

被引:26
作者
Alexandraki, Krystallenia I. [1 ]
Khan, Mohammed Munayem [1 ]
Chahal, Harvinder S. [1 ]
Dalantaeva, Nadezhda S. [1 ]
Trivellin, Giampaolo [1 ]
Berney, Dan M. [2 ]
Caron, Philippe [3 ]
Popovic, Vera [4 ]
Pfeifer, Marija [5 ]
Jordan, Suzanne [2 ]
Korbonits, Marta [1 ]
Grossman, Ashley B. [1 ]
机构
[1] Univ London St Bartholomews Hosp Med Coll, Coll Med, William Harvey Res Inst, Ctr Endocrinol, London EC1M 6BQ, England
[2] Barts & London Queen Marys Sch Med & Dent, Dept Histopathol, London, England
[3] CHU Larrey, Dept Endocrinol & Metab Dis, Toulouse, France
[4] Univ Clin Ctr, Endocrinol Clin, Neuroendocrine Unit, Belgrade, Serbia
[5] Univ Med Ctr Ljubljana, Dept Endocrinol Diabet & Metab Dis, Ljubljana, Slovenia
来源
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 2012年 / 11卷 / 03期
关键词
beta-galactosidase; Pituitary adenoma; Pituitary carcinoma; p16; p21; Senescence; CELLULAR SENESCENCE; TUMOR SUPPRESSION; CYTOPLASMIC LOCALIZATION; GROWTH; ACTIVATION; EXPRESSION; P21(CIP1); CELLS; CYCLE;
D O I
10.14310/horm.2002.1358
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: The model of 'oncogene-induced senescence' (OIS), resulting in cell-proliferation arrest, has recently been suggested as a possible explanation for the non-progression of pituitary tumours to malignancy. The aim of the study was to compare the expression of beta-galactosidase as a molecular marker of OIS, and p21/p16 as additional markers involved in mediating OIS, in pituitary adenomas, carcinomas and normal pituitary tissue. DESIGN: We performed: a) semi-quantitative immunohistochemistry (beta-galactosidase, p16, p21) in 41 pituitary adenomas [(11 GH-secreting, 9 PRL-secreting, 10 ACTH-secreting, 11 non-functioning (NFPAs)], 6 carcinomas (3 multihormonal: PRL/ACTH/GH, PRL/ACTH, PRL/GH/FSH; 1 non-functioning; 2 ACTH-secreting) and 7 normal pituitary tissues; b) quantitative PCR of mRNA (p16 and p21) in 6 GH-secreting, 6 NFPAs and 6 normal pituitary tissues. RESULTS: beta-galactosidase was significantly increased in GH-secreting tumours (P = 0.002), NFPAs (P = 0.04), macroadenomas (P = 0.03) and carcinomas (P = 0.02), as compared to normal pituitary tissue. We found that p16 expression was significantly lower in all tumours (both adenomas and carcinomas) probably secondary to reduced transcription, at least for NFPAs; p21 showed a different biological behaviour, implying that p21 and p16 may play different roles in the senescence of each individual type of adenoma. CONCLUSIONS: beta-galactosidase was significantly over-expressed in GH-secreting and NFPAs, and unexpectedly also in carcinomas. We speculate that the senescence pathway, which may explain the rarity of malignant progression to carcinomas in GH-secreting and NFPAs, might not be universal but cell-type specific.
引用
收藏
页码:297 / 307
页数:11
相关论文
共 29 条
[1]   Pituitary adenoma growth: A model for cellular senescence and cytokine action [J].
Arzt, Eduardo ;
Chesnokova, Vera ;
Stalla, Gueter K. ;
Melmed, Shlomo .
CELL CYCLE, 2009, 8 (05) :677-678
[2]   p21CiP1 restrains pituitary tumor growth [J].
Chesnokova, Vera ;
Zonis, Svetlana ;
Kovacs, Kalman ;
Ben-Shlomo, Anat ;
Wawrowsky, Kolja ;
Bannykh, Serguei ;
Melmed, Shlomo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) :17498-17503
[3]   Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth [J].
Chesnokova, Vera ;
Zonis, Svetlana ;
Rubinek, Tami ;
Yu, Run ;
Ben-Shlomo, Anat ;
Kovacs, Kalman ;
Wawrowsky, Kolia ;
Melmed, Shlomo .
CANCER RESEARCH, 2007, 67 (21) :10564-10572
[4]   Lineage-Specific Restraint of Pituitary Gonadotroph Cell Adenoma Growth [J].
Chesnokova, Vera ;
Zonis, Svetlana ;
Zhou, Cuiqi ;
Ben-Shlomo, Anat ;
Wawrowsky, Kolja ;
Toledano, Yoel ;
Tong, Yunguang ;
Kovacs, Kalman ;
Scheithauer, Bernd ;
Melmed, Shlomo .
PLOS ONE, 2011, 6 (03)
[5]   The power and the promise of oncogene-induced senescence markers [J].
Collado, Manuel ;
Serrano, Manuel .
NATURE REVIEWS CANCER, 2006, 6 (06) :472-476
[6]  
Donangelo I, 2005, J Endocrinol Invest, V28, P100
[7]   Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors [J].
Dworakowska, D. ;
Wlodek, E. ;
Leontiou, C. A. ;
Igreja, S. ;
Cakir, M. ;
Teng, M. ;
Prodromou, N. ;
Goth, M. I. ;
Grozinsky-Glasberg, S. ;
Gueorguiev, M. ;
Kola, B. ;
Korbonits, M. ;
Grossman, A. B. .
ENDOCRINE-RELATED CANCER, 2009, 16 (04) :1329-1338
[8]   Electron microscopy evidence that cytoplasmic localization of the p16INK4A "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact.: A study in non-small cell lung carcinomas [J].
Evangelou, K ;
Bramis, J ;
Peros, I ;
Zacharatos, P ;
Dasiou-Plakida, D ;
Kalogeropoulos, N ;
Asimacopoulos, PJ ;
Kittas, C ;
Marinos, E ;
Gorgoulis, VG .
BIOTECHNIC & HISTOCHEMISTRY, 2004, 79 (01) :5-10
[9]   Epigenetic change in pituitary tumorigenesis [J].
Farrell, WE ;
Clayton, RN .
ENDOCRINE-RELATED CANCER, 2003, 10 (02) :323-330
[10]   Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) [J].
Fernandez, Alberto ;
Karavitaki, Niki ;
Wass, John A. H. .
CLINICAL ENDOCRINOLOGY, 2010, 72 (03) :377-382